Demonstration Formulary
5 Infections
This formulary indicates prescribing status only, for guidance on managing infections please refer to your local antibiotic guidelines
Summary of antimicrobial prescribing guidance - managing common infections
05-03-01 Nucleoside reverse transcriptase inhibitors
| Emtricitabine 200mg, Rilpivirine 25mg and Tenofovir 245mg Eviplera® |
|
Formulary
|
Blueteq /prior approval form |
|
| Tenofovir Disproxil Viread® |
|
Non Formulary
|
 NICE CG165: Hepatitis B (chronic) - diagnosis and management NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil |
|
Links
- NICE CG165: Hepatitis B (chronic) - diagnosis and management
- NICE NG15: Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use
- NICE NG199: Clostridioides difficile infection: antimicrobial prescribing
- NICE NG79: Sinusitis (acute): antimicrobial prescribing
- NICE NG79: Sinusitis (acute): antimicrobial prescribing (visual summary)
- NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
- NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
- NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
- NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
- NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
- NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
- NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
- NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
- NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
- NICE TA757: Cabotegravir with rilpivirine for treating HIV-1
Summary of antimicrobial prescribing guidance - managing common infections